INDV.L

Indivior PLC [INDV.L] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

INDV.L Stock Summary

Earnings have grown 21.31% per last year.

Earnings are expected to fall -100% next year

Profit margins (-0.23%) are lower than the previous year (0%)

INDV.L has less than 1 year of cash runway

Top 10 Correlated ETFs

INDV.L

Top 10 Correlated Stocks

INDV.L

In the News

INDV.L Financial details

Company Rating

Buy

Market Cap

2.12B

Income

Revenue

1.09B

Book val./share

Cash/share

Dividend

Dividend %

Employees

1.16K

Optionable

Shortable

Yes

Earnings

22 Feb 2024

P/E

-8.94

Forward P/E

PEG

4.25

P/S

P/B

-87.54

P/C

P/FCF

-23.4

Quick Ratio

0.82

Current Ratio

0.98

Debt / Equity

LT Debt / Equity

EPS (TTM)

-0.3

EPS next Y

EPS next Q

EPS this Y

-102.63%

EPS next Y

EPS next 5Y

EPS last 5Y

-59.52%

Revenue last 5Y

6.84%

Revenue Q/Q

8.12%

EPS Q/Q

SMA20

-3.91%

SMA50

14.91%

SMA100

18.91%

Inst Own

Inst Trans

ROA

-13%

ROE

-435%

ROC

-0.49%

Gross Margin

83%

Oper. Margin

-29%

Profit Margin

-23%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1125.0-1938.0

52W High

-21.88%

52W Low

+34.58%

RSI

Rel Volume

0.48

Avg Volume

496.76K

Volume

237.74K

Perf Week

-6.83%

Perf Month

-11.93%

Perf Quarter

-3.93%

Perf Half Y

-3.87%

Beta

0.018

Volatility

36.29%, 56.18%

Prev Close

-0.66%

Price

1514

Change

-0.39%

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 496.76K
Market Capitalization 2.12B
Employee 1.16K
CEO Mr. Mark Crossley
Headquarters North Chesterfield,VA,US
IPO Date 2014-12-22
Website https://www.indivior.com

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.